Your browser doesn't support javascript.
loading
HIGH VERSUS STANDARD DOSES OF CORTICOSTEROIDS IN COVID-19 PATIENTS WITH AN ACUTE RESPIRATORY DISTRESS SYNDROME: a controlled observational comparative study.
Enric Monreal; Susana Sainz de la Maza; Elena Natera-Villalba; Alvaro Beltran-Corbellini; Fernando Rodriguez-Jorge; Jose Ignacio Fernandez-Velasco; Paulette Walo-Delgado; Alfonso Muriel; Javier Zamora; Araceli Alonso-Canovas; Jesus Fortun; Luis Manzano; Beatriz Montero-Errasquin; Lucienne Costa-Frossard; Jaime Masjuan; Luisa Maria Villar.
Afiliação
  • Enric Monreal; Department of Neurology, Hospital Universitario Ramon y Cajal, Universidad de Alcala, IRYCIS, Madrid, Spain.
  • Susana Sainz de la Maza; Department of Neurology, Hospital Universitario Ramon y Cajal, Universidad de Alcala, IRYCIS, Madrid, Spain.
  • Elena Natera-Villalba; Department of Neurology, Hospital Universitario Ramon y Cajal, Universidad de Alcala, IRYCIS, Madrid, Spain.
  • Alvaro Beltran-Corbellini; Department of Neurology, Hospital Universitario Ramon y Cajal, Universidad de Alcala, IRYCIS, Madrid, Spain.
  • Fernando Rodriguez-Jorge; Department of Neurology, Hospital Universitario Ramon y Cajal, Universidad de Alcala, IRYCIS, Madrid, Spain.
  • Jose Ignacio Fernandez-Velasco; Department of Immunology, Hospital Universitario Ramon y Cajal, Universidad de Alcala, IRYCIS, Madrid, Spain.
  • Paulette Walo-Delgado; Department of Immunology, Hospital Universitario Ramon y Cajal, Universidad de Alcala, IRYCIS, Madrid, Spain.
  • Alfonso Muriel; Biostatistics Unit, Hospital Universitario Ramon y Cajal, Universidad de Alcala, IRYCIS, CIBERESP, Madrid, Spain.
  • Javier Zamora; Biostatistics Unit, Hospital Universitario Ramon y Cajal, Universidad de Alcala, IRYCIS, CIBERESP, Madrid, Spain.
  • Araceli Alonso-Canovas; Department of Neurology, Hospital Universitario Ramon y Cajal, Universidad de Alcala, IRYCIS, Madrid, Spain.
  • Jesus Fortun; Department of Infectious Diseases, Hospital Universitario Ramon y Cajal, Universidad de Alcala, IRYCIS, Madrid, Spain.
  • Luis Manzano; Department of Internal Medicine, Hospital Universitario Ramon y Cajal, Universidad de Alcala, IRYCIS, Madrid, Spain.
  • Beatriz Montero-Errasquin; Department of Geriatrics, Hospital Universitario Ramon y Cajal, Universidad de Alcala, IRYCIS, Madrid, Spain.
  • Lucienne Costa-Frossard; Department of Neurology, Hospital Universitario Ramon y Cajal, Universidad de Alcala, IRYCIS, Madrid, Spain.
  • Jaime Masjuan; Department of Neurology, Hospital Universitario Ramon y Cajal, Universidad de Alcala, IRYCIS, Madrid, Spain.
  • Luisa Maria Villar; Department of Immunology, Hospital Universitario Ramon y Cajal, Universidad de Alcala, IRYCIS, Madrid, Spain.
Preprint em Inglês | medRxiv | ID: ppmedrxiv-20156315
ABSTRACT
INTRODUCTIONDespite the increasing evidence of the benefit of corticosteroids for the treatment of moderate-severe Coronavirus disease 2019 (COVID-19) patients, no data are available about the potential role of high doses of steroids for these patients. METHODSAll consecutive confirmed COVID-19 patients admitted to a single center were selected, including those treated with steroids and an acute respiratory distress syndrome (ARDS). Patients were allocated to the high doses (HD, [≥]250mg/day of methylprednisolone) of corticosteroids or the standard doses (SD, [≤]1.5mg/kg/day of methylprednisolone) at discretion of treating physician. The primary endpoint was the mortality between both cohorts and secondary endpoints were the risk of need for mechanical ventilation (MV) or death and the risk of developing a severe ARDS. RESULTS573 patients were included 428 (74.7%) men, with a median (IQR) age of 64 (54-73) years. In HD cohort, a worse baseline respiratory situation was observed and male sex, older age and comorbidities were significantly more common. After adjusting by baseline characteristics, HD were associated with a higher mortality than SD (adjusted-OR 2.46, 95% CI 1.58 - 3.83, p<0.001) and with an increased risk of needing MV or death (adjusted-OR 2.50, p=0.001). Conversely, the risk of developing a severe ARDS was similar between groups. Interaction analysis showed that HD increased mortality exclusively in elderly patients. CONCLUSIONOur real-world experience advises against exceeding 1-1.5mg/kg/day of corticosteroids for severe COVID-19 with an ARDS, especially in older subjects. This reinforces the rationale of modulating rather than suppressing immune responses in these patients. SUMMARYIn patients with severe COVID-19, high doses of corticosteroids are associated with a higher mortality and risk of need for mechanical ventilation or death compared to standard doses. This deleterious effect is mainly observed in the elderly.
Licença
cc_no
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Cohort_studies / Experimental_studies / Estudo observacional / Estudo prognóstico / Rct Idioma: Inglês Ano de publicação: 2020 Tipo de documento: Preprint
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Cohort_studies / Experimental_studies / Estudo observacional / Estudo prognóstico / Rct Idioma: Inglês Ano de publicação: 2020 Tipo de documento: Preprint
...